Close menu




January 27th, 2021 | 07:10 CET

GS Holdings Ltd., SAP SE, BB Biotech AG: Great services for society!

  • Investments
Photo credits: pixabay.com

The world is moving ever closer together. In the fight against the pandemic, the demand in the service industry is higher than ever. Distance and isolation, however, are the current opposing elements of daily life for everyone. However, for all areas of life, the service industry must continue to function under certain basic conditions. The guidelines are regulated. The adaptation of business models to the new rules of everyday life is taking place quickly, and companies and private individuals are taking the best possible route. More than ever, online presence, network availability, and a high level of service are among the guarantees of a functioning society. Asia is ahead of Europe in many respects, but when it comes to technology, biotech and medicine, the Western nations are currently still ahead!

time to read: 4 minutes | Author: André Will-Laudien
ISIN: SG1CF0000001 , DE0007164600 , CH0038389992

Table of contents:


    GS Holdings Ltd - Integrated ways in service

    One of the most Western-looking metropolises in Asia is undoubtedly Singapore. If it weren't permanently 30 degrees with almost 100% humidity, even Europeans would be able to stand it because the standard of living is very high. The city-state charges for the high level of service, so life in Singapore is not exactly cheap. The cleanliness, which can be felt everywhere and is strictly sanctioned, is impressive, and the punctuality of public transportation deserves an award. In the Covid pandemic, Singapore is taking a very regulated approach. The local people can feel "at ease" even with this burden because the impressive standard and security are always palpable and present.

    A highly flexible local service provider is GS Holdings Ltd, a specialist in providing end-to-end cleaning services to the food and beverage (F&B) industry. The investment holding Company focuses on two areas, with concepts covering the hospitality and lifestyle industries. Besides hospitality solutions such as dishwashing, they also offer franchise models and management services for restaurants, hotels and cafes. Known citywide are the three food courts in Bukit Batok and Sungei Kadut Way, a halal restaurant and a famous chicken and rice restaurant under the brand "Sing Swee Kee."

    "Raffles Coffee" has a Starbucks feel to it and, with its modern appearance, is considered a pearl for the future growth of the group. Marketing also comes from a single source, with subsidiary Wish Hospitality handling branding management for the startups, providing operational assistance and coordinating central procurement. A newer business line also includes recruitment and training for health and lifestyle centers or F&B outlets in China. The significantly higher standard is likely to be well received there, in particular.

    In this challenging environment, GS Holdings Ltd. will continue to add new service concepts and, if necessary, grow more strongly externally. The group is financially strong and makes half a million SGD profit per half-year. With modern service concepts for the local population, the story can now be rolled out perfectly.

    SAP SE - Data Analytics Subsidiary Aims for Nasdaq Listing

    SAP and Microsoft want to cooperate more closely in the future. According to recent statements, the integration of Microsoft Teams into existing SAP solutions is planned. The two companies wish to enable their customers to move more quickly to the cloud. SAP and Microsoft had already agreed to cooperate in 2019 to introduce new offerings in cloud automation and integration for SAP S/4-Hana on Microsoft Azure. The cloud segment, in particular, had disappointed recently, causing SAP's share price to plunge more than 30%.

    Apart from work on product integration, SAP, Microsoft and participating system integration partners will continue to provide roadmaps for the overall "Digital Enterprise" solution. These include reference architectures and technical support for user companies on their way to the cloud. Finally, the two software houses plan to increase investments in their platforms and infrastructure.

    According to a filing with the US Securities and Exchange Commission on Monday, at subsidiary Qualtrics, SAP raised the price range to USD 27 - 29 from the previous USD 22 - 26. This increase would mean revenues of up to USD 1.7 billion. In the best case, Qualtrics would now have a market value of around USD 15 billion, which would be almost double the takeover price that the Walldorf-based Company put on the table two years ago. Even after the IPO, SAP retains an 84% stake in Qualtrics. The Qualtrics platform allows companies and government agencies to collect feedback and data from customers and employees for real-time analysis and processing.

    The business model is reminiscent of Palantir. We believe that the growth of the new platform can accelerate very quickly. Partnerships with SAP competitors such as Salesforce.com or Workday, which were previously difficult to achieve, could also contribute. It feels like the turnaround at SAP has already happened and the course has been set correctly.

    BB Biotech AG - Profit increase and higher dividend

    BB Biotech AG has done a great job over the last 10 years. As a biotech investment Company, it posted slightly higher profits in the past fiscal year than in the previous year. Shareholders are to participate in this in the form of another dividend increase. According to Friday's AdHoc, the Company posted a net income of about SFR 691 million in 2020, up about 2% from the previous year. A regular dividend of SFR 3.60 per share is proposed to the annual general meeting on March 18, 2021 - another increase over the previous year's SFR 3.40 and quite a handy 5% yield.

    In particular, Moderna, in which BB Biotech has a stake, shot up significantly following the approval of the Corona vaccine. BB Biotech took profits in the fourth quarter accordingly, in addition to Moderna, Halozyme, Myovant, Crispr Therapeutics and Scholar Rock. The proceeds were mainly reinvested in the expansion of existing positions. In the final quarter, three new positions were added to the portfolio - Mersana, Biogen and Beam Therapeutics.

    In the current year 2021, the Company expects exciting fundamentals from the biotech sector and numerous vaccine campaigns against the Covid-19 virus. As a result, asset allocation is focused not only on established areas but also on rapidly developing future technologies. The new Biden administration's stance will play a significant role in healthcare. President Trump had rolled back some of the improvements from Obama Care; newcomer Biden is likely to be keen to push ahead again with drug pricing reform. Particularly in the Corona pandemic, improving access to necessary health care is expected to be a goal. BB Biotech remains well positioned with its US-heavy portfolio, boasting a 30% gain in one year. A solid story with a human touch!


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read